Similarly, the combination of arsenic trioxide (1 and 2 μM) and sorafenib/quizartinib (4 and 8 nM) showed synergistic anti-leukemia effects in FLT3-ITD AML cells (MOLM14 and MV-4-11) and primary cells from patients [28]. Here, FLT3 is linked to acute myeloid leukemia.